BU researchers find blood protein that may detect advanced CTE in living patients for first time
A small but striking study of 21 former football players found a specific protein spiked dramatically in those with advanced CTE — potentially opening the door to diagnosis before death.
For decades, the only way to confirm chronic traumatic encephalopathy was to examine a brain after its owner had died. A study published Thursday in the Journal of the American Medical Association suggests that may no longer have to be the case — at least eventually.
Researchers co-led by Boston University and Banner Health analyzed blood samples from 21 former football players who donated their brains to science, and found that a specific protein was dramatically elevated in those with the most advanced stages of CTE. The findings, announced at a scientific conference in Boston and simultaneously published in JAMA, represent the first time researchers have detected CTE neuropathology using only a blood test.
This is a game changer. We are still in the discovery phase and it's a small sample size, but if future studies validate these findings, this blood test will allow us to detect CTE with a high level of accuracy and open the doors to clinical trials and treatment.— Michael Alosco, co-director of clinical research, BU CTE Center
The protein at the center of the finding is called eMTBR-tau — endogenously cleaved microtubule-binding region tau — a marker of tau tangles that form inside neurons and can damage and kill them. Similar tangles appear in Alzheimer's disease. Of the 21 players studied, 18 had confirmed CTE at autopsy; of those, 16 had high-stage disease (McKee stage 3 or 4) and two had low-stage disease. Blood plasma eMTBR-tau concentrations were significantly higher in the high-stage group than in those with low-stage or no CTE.
What was really quite striking was just the difference. The high-stage CTE concentrations were just so much higher than anyone else, and that really stood out.— Michael Alosco, co-director of clinical research, BU CTE Center
The participants included 12 former professional, seven college, and two high school football players. Eleven of the 12 professional players had high-stage CTE. Five of the CTE cases also had Alzheimer's disease, and those individuals had the highest eMTBR-tau levels of all, according to bumc.bu.edu.
A key question for any future test is whether it can tell CTE apart from Alzheimer's, a disease with overlapping features. The researchers also measured a second biomarker, p-tau217, which is widely used to detect Alzheimer's. That marker was elevated only in participants who had Alzheimer's — not in those with CTE alone. Alosco said the combination of eMTBR-tau and p-tau217 could potentially detect CTE and differentiate it from Alzheimer's.
CTE is a neurodegenerative disease linked to repeated head impacts. Its symptoms most often include cognitive impairment, dementia, and behavior and mood changes. Because it can currently only be confirmed at autopsy, its true prevalence among living people is unknown, making it difficult to develop treatments or prevention strategies. A BU study published in October found that nearly 75 percent of NFL players who died between 2008 and 2023 had the disease. The condition has also been found in athletes in hockey, rugby, and soccer, and in military personnel.
The BU study was published alongside a second, independent paper in the same JAMA issue. Researchers at Washington University in St. Louis used a different method — mass spectrometry — and also found elevated eMTBR-tau in people with autopsy-confirmed CTE.
It's very encouraging that two independent groups with two independent methods came to the same conclusion.— Chihiro Sato, assistant professor of neurology, Washington University in St. Louis
Outside researchers welcomed the findings but were careful to frame them as a beginning, not a breakthrough ready for clinical use. Dr. Ramon Diaz-Arrastia, a neurology professor at the University of Pennsylvania Perelman School of Medicine who was not involved in the research, said the protein identified is exciting for the field but called the study's sample size too small to draw firm conclusions about diagnostic thresholds.
It's really just a hint. The sample size was way too small for us to make any guesses and any estimates as to what the diagnostic thresholds and things like that are.— Dr. Ramon Diaz-Arrastia, neurology professor, University of Pennsylvania Perelman School of Medicine
Derek Monroe, an assistant professor of exercise and sport science at UNC Chapel Hill, noted that the study participants are not representative of the broader population or even all football players, and that very few people with early-stage CTE or no disease were included.
Before we know how this test performs, it must be studied in a broader group of people: those with and without a history of head impacts, with and without symptoms, followed over time.— Derek Monroe, assistant professor of exercise and sport science, UNC Chapel Hill
Ultimately, I do not think any single marker will solve this. The more realistic path is a combination of tools.— Derek Monroe, assistant professor of exercise and sport science, UNC Chapel Hill
Michael Buckland, a clinical associate professor of pathology at the University of Sydney who was not involved in either study, called the combined findings a milestone, according to Scientific American.
It is a watershed moment for the field, demonstrating that fluid biomarkers can work in assisting diagnosis of CTE in the living. A confident CTE diagnosis in the living opens the door for clinical trials to start finding treatments for the disease.— Michael Buckland, clinical associate professor of pathology, University of Sydney
Researchers and study co-authors were explicit that the blood test is not FDA-approved, is not available to the public, and should not be used to make any diagnostic decisions until validation studies are completed, according to bumc.bu.edu. The BU CTE Center said people concerned about their brain health should seek evaluation from a clinician who specializes in neurodegenerative conditions.
The study's participants were drawn from ongoing NIH-funded projects including the DIAGNOSE CTE Research Project, which recruits men over 50 who played college or professional tackle football for thorough medical and neurological exams. Former NFL quarterback Matt Hasselbeck, a three-time All-Pro selection who played 18 seasons, became an ambassador for the project earlier this year and has submitted to testing in life, according to bu.edu. His father, former New England Patriot Don Hasselbeck, made the same brain-donation commitment before his death in 2025.
I was shocked when I first saw the data, as we have tested many biomarkers to this point and none have worked out until now.— Michael Alosco, co-director of clinical research, BU CTE Center
Alosco said the field is now well-positioned to run larger studies, with more former players participating and donating their brains. "In a not so distant future, we'll be able to do a larger one of these studies to validate it in a bigger sample," he told the Boston Globe. "If the findings hold up with future studies, this is really going to change the landscape."
Why it matters — If validated in larger studies, a blood test for CTE could allow doctors to diagnose and potentially treat the disease in living patients for the first time, transforming care for millions of contact-sport athletes and others at risk.
⚠ Not yet confirmed
- High-stage CTE has been diagnosed in athletes who died as young as their early 20s.
Reported by bu.edu, bumc.bu.edu, bostonglobe.com, scientificamerican.com
- Matt HasselbeckAmerican football player
- Michael BucklandBritish-American librarian